- Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
- Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
- Dyne Therapeutics Announces Proposed Public Offering of Common Stock
- Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
- Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
- Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
- Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
- Dyne Therapeutics Announces CEO Transition
More ▼
Key statistics
On Thursday, Dyne Therapeutics Inc (DYN:NSQ) closed at 32.51, -9.64% below its 52-week high of 35.98, set on May 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.85 |
---|---|
High | 33.06 |
Low | 31.97 |
Bid | 24.50 |
Offer | 33.50 |
Previous close | 32.51 |
Average volume | 1.41m |
---|---|
Shares outstanding | 97.59m |
Free float | 97.12m |
P/E (TTM) | -- |
Market cap | 3.11bn USD |
EPS (TTM) | -3.97 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼